Seroatlas · Human Serome Atlas

TNFSF11

Tumor necrosis factor ligand superfamily member 11

Also known as: CD254, ODF, OPGL, RANKL, TNF11_HUMAN, TRANCE

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
O14788
Gene
TNFSF11
Ensembl
ENSG00000120659
Chromosome
13
Canonical length
317 aa
Protein class
Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Human disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins
Secretome location
Secreted to blood
Quaternary structure
Homotrimer

OverviewNCBI Gene

This gene encodes a member of the tumor necrosis factor (TNF) cytokine family which is a ligand for osteoprotegerin and functions as a key factor for osteoclast differentiation and activation. This protein was shown to be a dentritic cell survival factor and is involved in the regulation of T cell-dependent immune response. T cell activation was reported to induce expression of this gene and lead to an increase of osteoclastogenesis and bone loss. This protein was shown to activate antiapoptotic kinase AKT/PKB through a signaling complex involving SRC kinase and tumor necrosis factor receptor-associated factor (TRAF) 6, which indicated this protein may have a role in the regulation of cell apoptosis. Targeted disruption of the related gene in mice led to severe osteopetrosis and a lack of osteoclasts. The deficient mice exhibited defects in early differentiation of T and B lymphocytes, and failed to form lobulo-alveolar mammary structures during pregnancy. Two alternatively spliced transcript variants have been found. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

317 residues, UniProt reviewed canonical sequence.

>O14788|TNFSF11
     1  MRRASRDYTK YLRGSEEMGG GPGAPHEGPL HAPPPPAPHQ PPAASRSMFV ALLGLGLGQV
    61  VCSVALFFYF RAQMDPNRIS EDGTHCIYRI LRLHENADFQ DTTLESQDTK LIPDSCRRIK
   121  QAFQGAVQKE LQHIVGSQHI RAEKAMVDGS WLDLAKRSKL EAQPFAHLTI NATDIPSGSH
   181  KVSLSSWYHD RGWAKISNMT FSNGKLIVNQ DGFYYLYANI CFRHHETSGD LATEYLQLMV
   241  YVTKTSIKIP SSHTLMKGGS TKYWSGNSEF HFYSINVGGF FKLRSGEEIS IEVSNPSLLD
   301  PDQDATYFGA FKVRDID

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TNFSF11 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
1
Mean surface accessibility (rSASA)
0.43
Highest tissue expression
12 nTPM

Expression across tissuesHPA

Tissue

  • lymph node: 12 nTPM
  • appendix: 4.3 nTPM
  • liver: 3.9 nTPM
  • tonsil: 3.5 nTPM
  • breast: 2.6 nTPM
  • rectum: 1.6 nTPM

Single-cell type

  • innate lymphoid cells: 147 nCPM
  • late spermatids: 35 nCPM
  • thymic myoid cells: 33 nCPM
  • breast hormone-responsive cells: 28 nCPM
  • early spermatids: 11 nCPM
  • respiratory ionocytes: 10 nCPM

Immune cell

  • NK-cell: 9.9 nTPM
  • basophil: 1.2 nTPM
  • memory CD4 T-cell: 0.1 nTPM
  • myeloid DC: 0.1 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM

Brain region

  • medulla oblongata: 1 nTPM
  • choroid plexus: 0.6 nTPM
  • hypothalamus: 0.4 nTPM
  • midbrain: 0.3 nTPM
  • amygdala: 0.2 nTPM
  • basal ganglia: 0.2 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about TNFSF11.

Disease | AllUniProt

Conditions TNFSF11 is implicated in, by any mechanism.

Disease | GeneticClinVar

5 pathogenic / likely-pathogenic of 264 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Disease | ImmuneIEDB

Conditions an epitope on TNFSF11 was assayed in.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.85
gnomAD pLI
0
gnomAD missense Z
0.93
DepMap mean gene effect
0.12
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of TNFSF11 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TNFSF11 as an antibody target. Whether an autoantibody or antibody against TNFSF11 could matter depends on whether native TNFSF11 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TNFSF11 is annotated at the cell surface, where native TNFSF11 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label TNFSF11 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/TNFSF11. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...